What the business is, and whether it's a good one at a fair price.
Manufactures and sells pharmaceutical products from a facility at Village Haripur, Panchkula, Haryana, generating Rs 147.58 crore in FY26 revenue, up 51% from Rs 97.52 crore the year before. The revenue base is built on third-party manufacturing orders combined with own-brand distribution, with the company investing in distribution channels and brand building during the year. Profitability softened: standalone EBITDA fell to Rs 13.80 crore (margin 9.35%) and standalone PAT slipped to Rs 4.52 crore, while consolidated PAT rose to Rs 5.35 crore. A fire on 27 April 2026 at the Panchkula factory caused Rs 9.39 crore of damage to building, plant, machinery and stocks, with the insurance claim still pending. Capital from a Rs 37.67 crore IPO in June 2025 was partly redirected into a 25.74% stake in Damaira Pharmaceuticals (Rs 6.25 crore) and into a US subsidiary, Astonea LLC in Wyoming, while the company also terminated its agreements with Astonea One Private Limited.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Not enough history to assess.How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from ASTONEA LABS LIMITED's filed financials and exchange disclosures
ASTONEA LABS LIMITED is a Pharmaceuticals & Biotechnology company listed on BSE.
Effectively yes. It holds ₹0 Cr more cash than debt.
On trailing P/E, ASTONEA LABS LIMITED ranks 153 of 169 in Pharmaceuticals — cheaper than 10% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session ASTONEA LABS LIMITED moves 1.53% — that is the median absolute close-to-close move across its last 215 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by ASTONEA LABS LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
